Developing stable and high-producing cell lines to manufacture biologics is complex, multi-stage, and time-consuming, often resulting in development timelines that exceed six months when using …
This $20 million 6,000 square meter facility will be operational in 2019 and provide integrated solutions from concept to commercialization for biologics conjugates including Antibody-Drug …
AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that in late 2017 it entered into a commercial supply …
Over the past seven years, Samsung BioLogics has constructed three state-of-the-art production facilities offering end-to-end integrated services to support the rapidly expanding clinical and commercial …
